A Phase II Study of Fruquintinib Plus Sintilimab As a Second-Line Therapy for Advanced Gastric and Gastroesophageal Junction Adenocarcinoma (GC/GEJC): Updated Results.
Journal of Clinical Oncology（2025）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要